Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Plaque Psoriasis Clear all

Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

NCT03589885

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more

Source: ClinicalTrials.gov public record

Updated Oct 10, 2021 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional Results available

An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis

NCT02407041

View directory record Official record

Conditions: Psoriasis
Interventions: GR-MD-02; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Sep 6, 2020 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

NCT00885196

View directory record Official record

Conditions: Moderate and Severe Plaque Psoriasis
Interventions: Placebo, AEB071; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 10
States / cities: Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more

Source: ClinicalTrials.gov public record

Updated Dec 21, 2020 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT04607980

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: ABP 654, Ustekinumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 30 more

Source: ClinicalTrials.gov public record

Updated Dec 11, 2024 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475

View directory record Official record

Conditions: Psoriasis
Interventions: Risankizumab, Apremilast; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 26
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more

Source: ClinicalTrials.gov public record

Updated Apr 29, 2024 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional Results available

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

NCT05223868

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more

Source: ClinicalTrials.gov public record

Updated Feb 12, 2026 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

NCT06088043

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: TAK-279, Placebo, Apremilast; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older

Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 24 more

Source: ClinicalTrials.gov public record

Updated Oct 23, 2025 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

NCT05272150

View directory record Official record

Conditions: Plaque Psoriasis, Scalp Psoriasis
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 79
States / cities: Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more

Source: ClinicalTrials.gov public record

Updated Sep 11, 2025 · Synced May 21, 2026, 10:11 PM EDT

Terminated Phase 3 Interventional Results available

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708629

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 1,881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 74
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more

Source: ClinicalTrials.gov public record

Updated Jan 2, 2020 · Synced May 21, 2026, 10:11 PM EDT

Terminated Not applicable Interventional Results available

Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

NCT00470392

View directory record Official record

Conditions: Psoriasis
Interventions: Imiquimod, Clobetasol; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Cleveland, Ohio

Source: ClinicalTrials.gov public record

Updated Oct 4, 2016 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 4 Interventional Results available

Plaque Psoriasis Study in Pediatric Subjects

NCT02186665

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: calcitriol ointment, placebo comparator; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 2 Years to 12 Years

Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Beverly Hills, California • Sacramento, California • Louisville, Kentucky + 9 more

Source: ClinicalTrials.gov public record

Updated Feb 17, 2021 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

NCT02660580

View directory record Official record

Conditions: Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: MSB11022, Humira®; Drug
Lead sponsor: Fresenius Kabi SwissBioSim GmbH; Industry
Eligibility: 18 Years and older

Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more

Source: ClinicalTrials.gov public record

Updated Dec 26, 2023 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional Results available

Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

NCT03764475

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: Roflumilast; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Beverly Hills, California • Northridge, California • San Diego, California + 16 more

Source: ClinicalTrials.gov public record

Updated Sep 1, 2022 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

Study of Secukinumab With 2 mL Pre-filled Syringes

NCT02748863

View directory record Official record

Conditions: Psoriasis
Interventions: Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more

Source: ClinicalTrials.gov public record

Updated Jul 14, 2019 · Synced May 21, 2026, 10:11 PM EDT

Active, not recruiting Phase 3 Interventional

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older

Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 46
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 42 more

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 21, 2026, 10:11 PM EDT

Terminated Phase 3 Interventional Results available

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

NCT03556202

View directory record Official record

Conditions: Psoriasis
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 1,936 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 47
States / cities: Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 41 more

Source: ClinicalTrials.gov public record

Updated Mar 20, 2023 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT05364554

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: Sacramento, California • Ocala, Florida • Tampa, Florida + 11 more

Source: ClinicalTrials.gov public record

Updated Sep 11, 2025 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03010527

View directory record Official record

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older

Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • Washington D.C., District of Columbia • West Des Moines, Iowa + 4 more

Source: ClinicalTrials.gov public record

Updated Oct 17, 2022 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

NCT02462070

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: IDP-118 Lotion, IDP-118 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Mobile, Alabama • Beverly Hills, California • Encino, California + 13 more

Source: ClinicalTrials.gov public record

Updated Aug 19, 2020 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 2 Interventional Results available

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

NCT03638258

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 20
States / cities: Beverly Hills, California • Northridge, California • San Diego, California + 16 more

Source: ClinicalTrials.gov public record

Updated Sep 1, 2022 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613

View directory record Official record

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis
Interventions: secukinumab low dose, secukinumab high dose; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years

Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more

Source: ClinicalTrials.gov public record

Updated May 15, 2025 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 4 Interventional

Bimekizumab in Plaque Psoriasis

NCT06336343

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: East Windsor, New Jersey • New York, New York

Source: ClinicalTrials.gov public record

Updated Apr 19, 2026 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 1 Interventional Results available

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

NCT01736696

View directory record Official record

Conditions: Psoriasis, Immunomodulation
Interventions: tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Little Rock, Arkansas

Source: ClinicalTrials.gov public record

Updated Feb 19, 2013 · Synced May 21, 2026, 10:11 PM EDT

Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

NCT04571567

View directory record Official record

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: Saakshi Khattri; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Apr 10, 2022 · Synced May 21, 2026, 10:11 PM EDT